HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spieker, L. E. Search for Related Content PubMed PubMed Citation Articles by Spieker, L. E.

Acute hemodynamic and neurohumoral effects of selective ET_A receptor blockade in patients with congestive heart failure

Lukas E. Spieker, MD^a, Veselin Mitrovic, MD^*, Georg Noll, MD, FESC^a, Richard Pacher, MD, Matthias R. Schulze, MD, J.örg Muntwyler, MD, MPH^a, Christoph Schalcher, MD^a, Wolfgang Kiowski, MD, FACC, FESC^a, Thomas F. Lüscher, MD, FACC, FRCP, FESC^a on behalf of the ET 003 Investigators

^a Division of Cardiology, University Hospital, Zürich, Switzerland
^* Kerckhoff Clinic, Bad Nauheim, Germany
Allgemeines Krankenhaus, Wien, Austria
Herz-und Kreislaufzentrum, Cardiology, Dresden, Germany

View larger version (16K): [in a new window]   Figure 1 Correlations between baseline endothelin (ET)-1 plasma levels and hemodynamic parameters in patients with chronic heart failure (n = 91). Mean pulmonary artery (MPAP, mm Hg; top) and pulmonary capillary wedge pressure (PCWP, mm Hg; middle) correlated positively with ET-1 plasma levels, while cardiac index (ml·min–1·m–2; bottom) was inversely associated with ET-1 levels.

View larger version (23K): [in a new window]   Figure 2 Changes of cardiac index and systemic vascular resistance 4 h after administration of different dosages of LU135252, a selective ETA receptor antagonist. *p < 0.05; **p 0.0002.

View larger version (21K): [in a new window]   Figure 3 Changes of endothelin-1 plasma levels after administration of various dosages of the selective ETA receptor antagonist LU135252. There was a dose-dependent increase in plasma ET-1 levels. *p < 0.003 vs. baseline.